TABLE 1.
Characteristics of the infected infants
| Patient no. | Maternal infectiona | Prenatal treatmentb | Onsetc | Clinical manifestationsd
|
Postnatal treatmente | ||
|---|---|---|---|---|---|---|---|
| RC | EC | HC | |||||
| T1 | II | Spir | B | − | + | − | − |
| T2 | II | Spir | Sub | − | − | − | − |
| T3 | III | Spir | Sub | − | − | − | − |
| T4 | III | Spir | Sub | − | − | − | − |
| T5 | III | P/S | B | + | − | − | − |
| T6 | II | P/S | B | − | + | − | − |
| T7 | II | P/S | Sub | − | − | − | − |
| T8 | III | P/S | B | − | + | − | − |
| T9 | III | P/S | Sub | − | − | − | − |
| T10 | III | P/S | B | + | + | + | + |
| T11 | III | Sub | − | − | − | − | |
| T12 | II | Spir | Sub | − | − | − | − |
| T13 | III | P/S | Sub | − | − | − | − |
| T14 | III | P/S | Sub | − | − | − | − |
| T15 | III | B | − | + | − | − | |
| T16 | III | Sub | − | − | − | − | |
| T17 | III | Spir | Sub | − | − | − | − |
| T18 | II | Spir | B | − | + | − | − |
| T19 | II | P/S | Sub | − | − | − | − |
| T20 | III | Sub | − | − | − | − | |
| T21 | III | P/S | S | + | + | − | − |
| T22 | III | P/S | Sub | − | − | − | − |
| T23 | II | Spir | Sub | − | − | − | − |
| T24 | II | P/S | B | − | + | − | − |
| T25 | II | P/S | S | + | + | + | + |
| T26 | II | Spir | S | + | + | + | + |
| T27 | III | Spir | Sub | − | − | − | − |
| T28 | II | Spir | S | + | + | − | + |
| T29 | III | Sub | − | − | − | − | |
| T30 | III | Spir | S | + | + | − | − |
| T31 | III | Sub | − | − | − | − | |
| T32 | III | P/S | Sub | − | − | − | − |
| T33 | III | P/S | Sub | − | − | − | − |
| T34 | III | P/S | Sub | − | − | − | + |
| T35 | III | P/S | Sub | − | − | − | − |
a
Trimester of gestation.
b
Spir, spiramycin; P/S, pyrimethamine-sulfadiazine in combination with spiramycin.
c
Severity of clinical onset: S, severe; B, benign; Sub, subclinical.
d
RC, retinochoroiditis; EC, endocranial calcifications; HC, hydrocephalus.
e
Treatment of the infected infant at the time of serum collection.